Therapy News and Research

RSS

New findings may lay groundwork of novel treatment for people with Huntington's disease

By adjusting the levels of a key signaling protein, researchers improved motor function and brain abnormalities in experimental animals with a form of Huntington's disease, a severe neurodegenerative disorder.

5 Jan 2015

Holding breath during radiation therapy can reduce radiation exposure to the heart

Women who have breast cancer on their left side present a particular challenge to radiation oncologists. Studies have shown that the risk of heart disease is higher in this group of women after radiation treatment because it can be difficult to ensure that a sufficient dose of radiation is delivered to the left breast while adequately shielding the heart from exposure.

5 Jan 2015

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients.

5 Jan 2015

Saatchi Bill: an interview with Dr. David Collingridge, Editor-in-Chief, The Lancet Oncology

The intention of the Medical Innovation Bill is to encourage and support doctors to explore new medicines for their patients when they believe existing options are no longer achieving good outcomes.

4 Jan 2015

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Cell biologists at UT Southwestern Medical Center have targeted telomeres with a small molecule called 6-thiodG that takes advantage of the cell's 'biological clock' to kill cancer cells and shrink tumor growth.

2 Jan 2015

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

2 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients.

31 Dec 2014

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Anthera Pharmaceuticals, Inc. today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.

31 Dec 2014

New therapeutic approach shows potential for treating cancer

Case Western Reserve researchers have identified a two-pronged therapeutic approach that shows great potential for weakening and then defeating cancer cells.

31 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

Making New Year's resolution to quit smoking a reality

Each year on January 1st, Americans make goals for the New Year, ranging from getting in shape and spending more time with their families to decreasing debt. This year, make a resolution that will not only improve your health, but also save you money— quit smoking. According to the Surgeon General's most recent tobacco-related report, cigarette smoking is the leading cause of preventable disease and premature death worldwide.

30 Dec 2014

InformedDNA and NIA Magellan to jointly offer evidence-based genetic benefits optimization program

InformedDNA announced today that it will collaborate with NIA Magellan, a division of Magellan Health, Inc., to offer an evidence-based genetic benefits optimization program. InformedDNA's national network of independent board-certified genetics specialists provides expert clinical review services to ensure appropriate use of genetic testing and improve patient care, while at the same time delivering significant cost savings.

30 Dec 2014

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Novastem, a leader in regenerative medicine, announces the treatment of its first patient in its study for ischemic stroke at Clinica Santa Clarita.

25 Dec 2014

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop resistance to otherwise lethal therapies.

24 Dec 2014

Therapy News and Research

New findings may lay groundwork of novel treatment for people with Huntington's disease

Holding breath during radiation therapy can reduce radiation exposure to the heart

Study: Placental cells may possibly treat damaged nerves

Saatchi Bill: an interview with Dr. David Collingridge, Editor-in-Chief, The Lancet Oncology

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

New therapeutic approach shows potential for treating cancer

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Making New Year's resolution to quit smoking a reality

InformedDNA and NIA Magellan to jointly offer evidence-based genetic benefits optimization program

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Newron, Zambon announce re-submission of safinamide NDA to FDA

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News